Aug 24 2010
Ensemble Therapeutics announced today the presentation of data on its macrocyclic-based drug discovery platform at the American Chemical Society (ACS) National Meeting August 22-26, in Boston at the Boston Convention and Exposition Center.
“With their unique macrocyclic structure, Ensemblins are a new class of orally-active drugs with unique properties for binding to a large number of historically challenging human disease targets.”
Poster Presentations:
- #222: Tuesday, August 24, 2010, 5:30 p.m., "The Rapid Creation and Selection of Macrocyclic Libraries for the Modulation of Protein-Protein Interactions", Connors, et.al, Exhibit Hall C.
- #667: Tuesday, August 24, 2010, 8:00 p.m., Division of Organic Chemistry, "The Rapid Creation and Screening of Peptidic-Macrocyclic Libraries against Protein-Protein Interactions", Yan, et.al., Exhibit Hall C.
- #429: Wednesday, August 25, 2010, 7:00 p.m., Division of Medicinal Chemistry, "Drug-Like Properties Of Macrocyclic Molecules Derived From DNA-Programmed Combinatorial Libraries", Seigal, et.al, Ballroom.
Special Oral Presentation:
- #62: Young Investigators Symposium, Sunday, August 22, 2010, 9:15 a.m.
"DNA-Programmed Chemistry Approaches to Macrocyclic Lead Compounds", Fraley, et.al, Room 205A/B. This symposium highlights up-and-coming investigators who have demonstrated outstanding promise for future contributions to organic chemistry.
"The body of data presented at ACS this year demonstrates Ensemble's progress in deploying our proprietary DNA-programmed drug discovery platform to assess large numbers of macrocycles with the goal of rapidly optimizing lead drug candidates for development of novel macrocycle-based therapeutics," said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics. "With their unique macrocyclic structure, Ensemblins are a new class of orally-active drugs with unique properties for binding to a large number of historically challenging human disease targets."
AI-powered method predicts protein dynamics to accelerate drug discovery